Holen Sie sich die Stockscreener-App
0.3929
1.06%
-0.0042
Handel nachbörslich:
.72
0.3271
+83.25%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$0.3971
Offen:
$0.3964
24-Stunden-Volumen:
2.32M
Relative Volume:
1.31
Marktkapitalisierung:
$102.70M
Einnahmen:
$9.10M
Nettoeinkommen (Verlust:
$-82.47M
KGV:
-0.6774
EPS:
-0.58
Netto-Cashflow:
$-72.32M
1W Leistung:
-5.73%
1M Leistung:
-6.36%
6M Leistung:
-37.17%
1J Leistung:
-50.60%
1-Tages-Spanne:
$0.3824
$0.409
1-Wochen-Bereich:
$0.3824
$0.42
52-Wochen-Spanne:
$0.285
$1.07
Vaxart Inc Stock (VXRT) Company Profile
Firmenname
Vaxart Inc
Sektor
Branche
Telefon
(650) 550-3500
Adresse
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie VXRT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.3929 | 102.70M | 9.10M | -82.47M | -72.32M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.52 | 114.39B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
523.53 | 52.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
302.46 | 39.91B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.46 | 35.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
263.42 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-15 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-29 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-06-24 | Eingeleitet | Jefferies | Buy |
| 2021-06-11 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
Alle ansehen
Vaxart Inc Aktie (VXRT) Neueste Nachrichten
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial | VXRT Stock News - GuruFocus
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - GlobeNewswire
Vaxart to Reveal First-Ever Oral Norovirus Vaccine Trial Results: Key Data Coming Tomorrow - Stock Titan
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 | VXRT Stock News - GuruFocus
Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP Announce a Class Action for All Vaxart Shareholders that May Include You, Even if You Participated in the Previous Partial Settlement with Vaxart - Business Wire
Vaxart Announces Adjournment of Annual Meeting of Stockholders | - GuruFocus
Vaxart Announces Adjournment Of Annual Meeting Of Stockholders - marketscreener.com
Vaxart Announces Adjournment of Annual Meeting of Stockholders | VXRT Stock News - GuruFocus
Vaxart Annual Meeting Adjourned to June 13, 2025; Proxy Advisory Firms Support Proposal No. 2 - Nasdaq
Vaxart Announces Adjournment of Annual Meeting of Stockholders - GlobeNewswire
Vaxart stock climbs on positive study of pill-based norovirus vaccine - MSN
Zoom Rises 8% in 3 Months: Here's Why You Should Buy the Stock Now - The Globe and Mail
Vaxart seeks shareholder nod for reverse stock split By Investing.com - Investing.com South Africa
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 - The Manila Times
Vaxart Leaders Set for Key Fireside Chat at Major Healthcare Conference: What to Expect - Stock Titan
Vaxart (VXRT) Releases Video Update Urging Support for Reverse S - GuruFocus
Vaxart seeks shareholder nod for reverse stock split - Investing.com Australia
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders | VXRT Stock News - GuruFocus
Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders - GlobeNewswire
Vaxart Founder Makes Urgent Appeal: Critical Nasdaq Compliance Vote Deadline Approaches - Stock Titan
Vaxart Discusses Reverse Stock Split and Capital Raise - TipRanks
Vaxart Answers Additional Frequently Asked Questions from Retail Investors - GlobeNewswire
Vaxart (VXRT) Addresses Stockholder Concerns Ahead of Annual Mee - GuruFocus
Vaxart Begins Phase 2b Trial for Oral COVID-19 Vaccine - TipRanks
Vaxart (VXRT) Addresses Stockholder Concerns Ahead of Annual Meeting | VXRT Stock News - GuruFocus
Vaxart Reveals New Split Ratio Details as Nasdaq Delisting Deadline LoomsCEO Urges Action - Stock Titan
USDJPY Faces An Intraday Corrective Recovery: Elliott Wave Intraday Analysis - The Globe and Mail
Vaxart (VXRT) Advances in Phase 2b Trial with Oral COVID-19 Vacc - GuruFocus
Vaxart Initiates Dosing In 10,000-Participant Portion Of Phase 2B Covid-19 Trial - marketscreener.com
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Vaxart (VXRT) Advances in Phase 2b Trial with Oral COVID-19 Vaccine | VXRT Stock News - GuruFocus
Breakthrough Oral COVID Vaccine Pill Advances: Vaxart Launches Massive 10,000-Patient Trial with $460M Backing - Stock Titan
RFK Jr issues bombshell order on Covid vaccine over safety concerns - MSN
Vaxart (NASDAQ:VXRT) Upgraded at Wall Street Zen - Defense World
Vaxart Urges Stockholder Action: Crucial Nasdaq Compliance Vote Delayed as Reverse Split Hangs in Balance - Stock Titan
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock News - GuruFocus
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman - Nasdaq
Vaxart Lures New CFO With Massive 1.35M Share Package: Inside the Compensation Deal - Stock Titan
Vaxart Approves Resolutions to Narrow Proposed Reverse - GlobeNewswire
Vaxart seeks approval for reverse stock split to retain Nasdaq listing By Investing.com - Investing.com South Africa
Vaxart Limits Reverse Stock Split To 1-for-20 In Response To Shareholder Feedback - Nasdaq
Vaxart Board Approves Reverse Split Proposal - TipRanks
Vaxart seeks approval for reverse stock split to retain Nasdaq listing - Investing.com Nigeria
Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs - MSN
Vaxart (VXRT) Eyes Reverse Stock Split to Secure Nasdaq Listing | VXRT Stock News - GuruFocus
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting | VXRT Stock News - GuruFocus
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting - The Globe and Mail
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Vaxart gets nod to expand COVID-19 pill vaccine trial By Investing.com - Investing.com South Africa
Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial - marketscreener.com
Finanzdaten der Vaxart Inc-Aktie (VXRT)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.65%
1.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):